Skeletal abnormalities caused by a Connexin43_R239Q mutation in a mouse model for autosomal recessive craniometaphyseal dysplasia

Abstract

Craniometaphyseal dysplasia (CMD), a rare craniotubular disorder, occurs in an autosomal dominant (AD) or autosomal recessive (AR) form. CMD is characterized by hyperostosis of craniofacial bones and metaphyseal flaring of long bones. Many patients with CMD suffer from neurological symptoms. The pathogenesis of CMD is not fully understood. Treatment is limited to craniofacial surgery. Here, we report a knock in (KI) mouse model for AR CMD carrying a Cx43_R239Q mutation. Cx43 ^KI/KI mice replicate typical features of AR CMD, including thickening of craniofacial bones, club-shaped femurs, and widened diaphyseal cortical bones. Female Cx43 ^KI/KI mice display remarkably more bone overgrowth than male Cx43 ^KI/KI mice as they age. In contrast to Cx43 ^+/+ littermates, Cx43 ^KI/KI mice exhibit periosteal bone deposition and increased osteoclast (OC) numbers in the endosteum of long bones. Although formation of resting OCs in Cx43 ^+/+ and Cx43 ^KI/KI mice is comparable, the actively resorbing Cx43 ^KI/KI OCs have reduced resorption on bone chips. Cx43 ^KI/KI mice display reduced osteocyte dendrites. RNA from Cx43 ^KI/KI femoral cortical bones show reduced expression levels of Sost, Tnf-α, IL-1β, Esr1, Esr2, and a lower Rankl/Opg ratio. Moreover, the Cx43_R239Q mutation results in altered spatial expression of Cx43 protein and mild reduction of gap junction and hemichannel activity. The distinct phenotype seen in Cx43 ^KI/KI mice but not in Cx43 ablation models suggests that Cx43 loss-of-function is unlikely the main cause of AR CMD. Additional studies are required to investigate new roles of CMD-mutant Cx43.

References

[1] Jackson, W. P., Albright, F., Drewry, G., Hanelin, J. & Rubin, M. I. Metaphyseal dysplasia, epiphyseal dysplasia, diaphyseal dysplasia, and related conditions. I. Familial metaphyseal dysplasia and craniometaphyseal dysplasia; their relation to leontiasis ossea and osteopetrosis; disorders of bone remodeling. A.M.A. Arch. Internal Med. 94, 871–885 (1954).

[2] Reichenberger, E. & Chen, I. P. in GeneReviews(R) (eds R. A. Pagon et al.) (1993).

[3] Ramseyer LT, Leonard JC, Stacy TM. Bone scan findings in craniometaphyseal dysplasia Clin. Nucl. Med., 1993, 18: 137-139.

[4] Hayashibara T, Komura T, Sobue S, Ooshima T. Tooth eruption in a patient with craniometaphyseal dysplasia: case report J. Oral. Pathol. Med. : Off. Publ. Int. Assoc. Oral. Pathologists Am. Acad. Oral. Pathol., 2000, 29: 460-462.

[5] Cai C, Zhang Q, Shen C, Sun G, Wang C. Chiari malformation caused by craniometaphyseal dysplasia: case report and review of literature Eur. J. Pediatr. Surg., 2008, 18: 198-201.

[6] Tanaka M, et al.. Chiari type I malformation caused by craniometaphyseal dysplasia Acta Med. Okayama, 2013, 67: 385-389

[7] Reichenberger E, et al.. Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK Am. J. Hum. Genet., 2001, 68: 1321-1326.

[8] Nurnberg P, et al.. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia Nat. Genet., 2001, 28: 37-41.

[9] Hu Y, et al.. A novel autosomal recessive GJA1 missense mutation linked to Craniometaphyseal dysplasia PLoS One, 2013, 8: e73576.

[10] Liu Y, Dutra EH, Reichenberger EJ, Chen IP. Dietary phosphate supplement does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia J. Negat. Results Biomed., 2016, 15: 18.

[11] Yamamoto T, et al.. Bone marrow-derived osteoclast-like cells from a patient with craniometaphyseal dysplasia lack expression of osteoclast-reactive vacuolar proton pump J. Clin. Investig., 1993, 91: 362-367.

[12] Chen IP, et al.. Introduction of a Phe377del mutation in ANK creates a mouse model for craniometaphyseal dysplasia J. Bone Miner. Res., 2009, 24: 1206-1215.

[13] Saez JC, Berthoud VM, Branes MC, Martinez AD, Beyer EC. Plasma membrane channels formed by connexins: their regulation and functions Physiol. Rev., 2003, 83: 1359-1400.

[14] Nielsen MS, et al.. Gap junctions Compr. Physiol., 2012, 2: 1981-2035.

[15] Alexander DB, Goldberg GS. Transfer of biologically important molecules between cells through gap junction channels Curr. Med Chem., 2003, 10: 2045-2058.

[16] Goodenough DA, Goliger JA, Paul DL. Connexins, connexons, and intercellular communication Annu. Rev. Biochem, 1996, 65: 475-502.

[17] Pacheco-Costa R, et al.. High bone mass in mice lacking Cx37 because of defective osteoclast differentiation J. Biol. Chem., 2014, 289: 8508-8520.

[18] Stains JP, Civitelli R. Gap junctions in skeletal development and function Biochim. Biophys. Acta, 2005, 1719: 69-81.

[19] Zimmermann B. Assembly and disassembly of gap junctions during mesenchymal cell condensation and early chondrogenesis in limb buds of mouse embryos J. Anat., 1984, 138: 351-363

[20] Civitelli R, et al.. Connexin43 mediates direct intercellular communication in human osteoblastic cell networks J. Clin. Investig., 1993, 91: 1888-1896.

[21] Yellowley CE, Li Z, Zhou Z, Jacobs CR, Donahue HJ. Functional gap junctions between osteocytic and osteoblastic cells J. Bone Miner. Res., 2000, 15: 209-217.

[22] Koval M, Harley JE, Hick E, Steinberg TH. Connexin46 is retained as monomers in a trans-Golgi compartment of osteoblastic cells J. Cell Biol., 1997, 137: 847-857.

[23] Paic F, et al.. Identification of differentially expressed genes between osteoblasts and osteocytes Bone, 2009, 45: 682-692.

[24] Kelly JJ, Simek J, Laird DW. Mechanisms linking connexin mutations to human diseases Cell Tissue Res., 2015, 360: 701-721.

[25] Richardson RJ, et al.. A nonsense mutation in the first transmembrane domain of connexin 43 underlies autosomal recessive oculodentodigital syndrome J. Med. Genet., 2006, 43: e37.

[26] Paznekas WA, et al.. Connexin 43 (GJA1) mutations cause the pleiotropic phenotype of oculodentodigital dysplasia Am. J. Hum. Genet., 2003, 72: 408-418.

[27] Lecanda F, et al.. Connexin43 deficiency causes delayed ossification, craniofacial abnormalities, and osteoblast dysfunction J. Cell Biol., 2000, 151: 931-944.

[28] Watkins M, et al.. Osteoblast connexin43 modulates skeletal architecture by regulating both arms of bone remodeling Mol. Biol. Cell, 2011, 22: 1240-1251.

[29] Grimston SK, Watkins MP, Brodt MD, Silva MJ, Civitelli R. Enhanced periosteal and endocortical responses to axial tibial compression loading in conditional connexin43 deficient mice PloS One, 2012, 7: e44222.

[30] Chung DJ, et al.. Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice with an osteoblast-specific deletion of connexin43 J. Cell Sci., 2006, 119: 4187-4198.

[31] Grimston SK, Brodt MD, Silva MJ, Civitelli R. Attenuated response to in vivo mechanical loading in mice with conditional osteoblast ablation of the connexin43 gene (Gja1) J. Bone Miner. Res., 2008, 23: 879-886.

[32] Gonzalez-Nieto D, et al.. Connexin-43 in the osteogenic BM niche regulates its cellular composition and the bidirectional traffic of hematopoietic stem cells and progenitors Blood, 2012, 119: 5144-5154.

[33] Plotkin LI, et al.. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo J. Bone Miner. Res., 2008, 23: 1712-1721.

[34] Zhang Y, et al.. Enhanced osteoclastic resorption and responsiveness to mechanical load in gap junction deficient bone PLoS One, 2011, 6: e23516.

[35] Bivi N, et al.. Cell autonomous requirement of connexin 43 for osteocyte survival: consequences for endocortical resorption and periosteal bone formation J. Bone Miner. Res., 2012, 27: 374-389.

[36] Lloyd SA, Lewis GS, Zhang Y, Paul EM, Donahue HJ. Connexin 43 deficiency attenuates loss of trabecular bone and prevents suppression of cortical bone formation during unloading J. Bone Miner. Res., 2012, 27: 2359-2372.

[37] Flenniken AM, et al.. A Gja1 missense mutation in a mouse model of oculodentodigital dysplasia Development, 2005, 132: 4375-4386.

[38] Kalcheva N, et al.. Gap junction remodeling and cardiac arrhythmogenesis in a murine model of oculodentodigital dysplasia Proc. Natl. Acad. Sci. USA, 2007, 104: 20512-20516.

[39] Dobrowolski R, et al.. The conditional connexin43G138R mouse mutant represents a new model of hereditary oculodentodigital dysplasia in humans Hum. Mol. Genet., 2008, 17: 539-554.

[40] Shibayama J, et al.. Functional characterization of connexin43 mutations found in patients with oculodentodigital dysplasia Circ. Res., 2005, 96: e83-e91.

[41] McLachlan E, et al.. ODDD-linked Cx43 mutants reduce endogenous Cx43 expression and function in osteoblasts and inhibit late stage differentiation J. Bone Miner. Res., 2008, 23: 928-938.

[42] Prontera P, et al.. Craniometaphyseal dysplasia with severe craniofacial involvement shows homozygosity at 6q21-22.1 locus Am. J. Med. Genet. Part A, 2011, 155A: 1106-1108.

[43] Shimada T, et al.. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia Proc. Natl. Acad. Sci. USA, 2001, 98: 6500-6505.

[44] White KE, et al.. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23 Kidney Int., 2001, 60: 2079-2086.

[45] Chen IP, et al.. Dental anomalies associated with craniometaphyseal dysplasia J. Dent. Res., 2014, 93: 553-558.

[46] Qin L, Liu W, Cao H, Xiao G. Molecular mechanosensors in osteocytes Bone Res., 2020, 8: 23.

[47] Kanaji A, et al.. Co-Cr-Mo alloy particles induce tumor necrosis factor alpha production in MLO-Y4 osteocytes: a role for osteocytes in particle-induced inflammation Bone, 2009, 45: 528-533.

[48] Pesce Viglietti AI, et al.. Brucella abortus invasion of osteocytes modulates connexin 43 and integrin expression and induces osteoclastogenesis via receptor activator of NF-kappaB ligand and tumor necrosis factor alpha secretion Infect. Immun., 2016, 84: 11-20.

[49] Kulkarni RN, Bakker AD, Everts V, Klein-Nulend J. Mechanical loading prevents the stimulating effect of IL-1beta on osteocyte-modulated osteoclastogenesis Biochem. Biophys. Res. Commun., 2012, 420: 11-16.

[50] Winkler DG, et al.. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist EMBO J., 2003, 22: 6267-6276.

[51] Nakashima T, et al.. Evidence for osteocyte regulation of bone homeostasis through RANKL expression Nat. Med., 2011, 17: 1231-1234.

[52] Ross MW, Altman DH. Familial metaphyseal dysplasia. Review of the clinical and radiologic feature of Pyle’s disease Clin. Pediatr. (Philos.), 1967, 6: 143-149.

[53] Penchaszadeh VB, Gutierrez ER, Figueroa E. Autosomal recessive craniometaphyseal dysplasia Am. J. Med. Genet., 1980, 5: 43-55.

[54] Elcioglu N, Hall CM. Temporal aspects in craniometaphyseal dysplasia: autosomal recessive type Am. J. Med. Genet., 1998, 76: 245-251.

[55] Iughetti P, Alonso LG, Wilcox W, Alonso N, Passos-Bueno MR. Mapping of the autosomal recessive (AR) craniometaphyseal dysplasia locus to chromosome region 6q21-22 and confirmation of genetic heterogeneity for mild AR spondylocostal dysplasia Am. J. Med. Genet., 2000, 95: 482-491.

[56] Beighton P, Hamersma H, Horan F. Craniometaphyseal dysplasia-variability of expression within a large family Clin. Genet., 1979, 15: 252-258.

[57] Kanaujiya J, et al.. Rapid degradation of progressive ankylosis protein (ANKH) in craniometaphyseal dysplasia Sci. Rep., 2018, 8. 15710

[58] Giepmans BN, et al.. Gap junction protein connexin-43 interacts directly with microtubules Curr. Biol., 2001, 11: 1364-1368.

[59] Dai P, Nakagami T, Tanaka H, Hitomi T, Takamatsu T. Cx43 mediates TGF-beta signaling through competitive Smads binding to microtubules Mol. Biol. cell, 2007, 18: 2264-2273.

[60] Saidi Brikci-Nigassa A, et al.. Phosphorylation controls the interaction of the connexin43 C-terminal domain with tubulin and microtubules Biochemistry, 2012, 51: 4331-4342.

[61] Balemans W, et al.. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST) Hum. Mol. Genet., 2001, 10: 537-543.

[62] Pfeilschifter J, Chenu C, Bird A, Mundy GR, Roodman GD. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro J. Bone Miner. Res., 1989, 4: 113-118.

[63] Komm BS, et al.. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells Science, 1988, 241: 81-84.

[64] Onoe Y, Miyaura C, Ohta H, Nozawa S, Suda T. Expression of estrogen receptor beta in rat bone Endocrinology, 1997, 138: 4509-4512.

[65] Vidal O, Kindblom LG, Ohlsson C. Expression and localization of estrogen receptor-beta in murine and human bone J. Bone Miner. Res., 1999, 14: 923-929.

[66] Sims NA, et al.. A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor-deficient mice J. Clin. Investig., 2003, 111: 1319-1327.

[67] Sims NA, et al.. Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males Bone, 2002, 30: 18-25.

[68] Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses Nat. Rev. Genet., 2012, 13: 227-232.

[69] Kosti I, Jain N, Aran D, Butte AJ, Sirota M. Cross-tissue analysis of gene and protein expression in normal and cancer tissues Sci. Rep., 2016, 6. 24799

[70] Perl K, et al.. Reduced changes in protein compared to mRNA levels across non-proliferating tissues BMC Genomics, 2017, 18. 305

[71] Hong, S. H. et al. Computer-automated static, dynamic and cellular bone histomorphometry. J. Tissue Sci. Eng. Suppl 1, 004 https://doi.org/10.4172/2157-7552.S1-004 (2012).

[72] Rowe DW, et al.. Screening gene knockout mice for variation in bone mass: Analysis by muCT and histomorphometry Curr. Osteoporos. Rep., 2018, 16: 77-94.

[73] Cox WG, Singer VL. A high-resolution, fluorescence-based method for localization of endogenous alkaline phosphatase activity J. Histochem. Cytochem., 1999, 47: 1443-1456.

[74] Kalajzic I, et al.. Use of type I collagen green fluorescent protein transgenes to identify subpopulations of cells at different stages of the osteoblast lineage J. Bone Miner. Res., 2002, 17: 15-25.

[75] Chen IP, Wang L, Jiang X, Aguila HL, Reichenberger EJ. A Phe377del mutation in ANK leads to impaired osteoblastogenesis and osteoclastogenesis in a mouse model for craniometaphyseal dysplasia (CMD) Hum. Mol. Genet., 2011, 20: 948-961.

[76] Stern AR, et al.. Isolation and culture of primary osteocytes from the long bones of skeletally mature and aged mice Biotechniques, 2012, 52: 361-373.

Funding

U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR)(DE025664)

RIGHTS & PERMISSIONS

The Author(s)